Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →FierceBiotech's contemporaneous take: the modest $150M upfront 'indicated a lack of interest among the big players,' and Afrezza faced 'heavy skepticism'…
Market feared "MannKind isn't getting enough in the deal when you consider how long and costly the saga of getting Afrezza approved was," plus "a fear that…
STAT framed the termination as confirmation that inhaled insulin remained commercially unviable, with Piper Jaffray's Joshua Schimmer arguing MannKind was…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi licensed worldwide rights to MannKind's Afrezza inhaled insulin for $150M upfront plus up to $775M in regulatory and sales milestones with profit share. Strategically high-profile but ultimately unsuccessful—Sanofi terminated the alliance in January 2016 amid weak launch performance.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / MannKind Corporation (this deal) | 2014 | $925M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2014 deals · Sanofi SA deals · Metabolic deals